Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

A large real-world study in southern China found that adding daratumumab to first-line multiple myeloma therapy significantly improves patient outcomes. The research demonstrates increased response depth, higher MRD negativity, and superior 3-year progression-free survival. Even with limited treatment cycles due to costs, daratumumab remains a highly effective option for enhancing patient survival and overall clinical disease control.